Loading company
Insight Molecular Diagnostics Inc.
IMDX · Nasdaq · ·
Next earnings: November 9, 2026
$3.38+6.5%Sep 29 close
- 1M
- -18.3%
- 6M
- +32.4%
- 1Y
- +1.7%
- 5Y
- -95.7%
Insight Molecular Diagnostics Inc. is the 35th largest of 41 graded companies. Showing 5 of them, including IMDX itself. 3 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Burning Rock Biotech LimitedBNR | C- | — | $80.4M | -10.3% | -$5M | — |
| Thermo Fisher Scientific Inc.TMO | A+ | $251.4B | $46.3B | 15.0% | $7.3B | 36.58 |
| Danaher CorporationDHR | C+ | $159B | $25.1B | 15.9% | $5.5B | 40.16 |
| Natera, Inc.NTRA | B- | $59.7B | $2.7B | -7.1% | $84.2M | — |
| Insight Molecular Diagnostics Inc.IMDX | D | $110.4M | $1.7M | -2,955.6% | -$31M | — |
36 more diagnostics and research companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Insight Molecular Diagnostics Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
IMDX · Nasdaq · ·
Next earnings: November 9, 2026
$3.38+6.5%Sep 29 close